Health Care • Medicinal Chemicals and Botanical Products
$2.64 ▼ -0.05
(-1.86%)
MKT CAP: $390.2M • VOL: 4.21M
52W L $2 52W H $16
TLRY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-05-31 | FY 2024
FILED 2025-05-31 | FY 2023
FILED 2024-05-31 |
|---|---|---|---|
| Revenue (Total Sales) | $915.5M | $821.3M | $788.9M |
| YoY Revenue Growth % | +11.5% | +4.1% | — |
| Gross Profit | $260.4M | $240.6M | — |
| Gross Margin % | 28.4% | 29.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$63.0M | -$2.28B | -$174.7M |
| Operating Margin % | -6.9% | -80.0% | -22.1% |
| Net Income (GAAP) | -$121.4M | -$2.19B | -$245.0M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$69.1M | -$94.6M | -$30.9M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$69.1M | -$94.6M | -$30.9M |
| FCF Margin % | -7.6% | -11.5% | -3.9% |
| Return on Invested Capital (ROIC %) | -3.9% | -45.0% | — |
| Cash & Short-Term Equivalents | $221.7M | $200.0M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $1.51B | $2.73B | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TLRY.